



For more information, please contact the Neuro-Oncology Clinical Trial Team at: neuro.oncology@jwci.org 310-829-8265

Clinical Trial Investigators

Garni Barkhoudarian, MD

Daniel Kelly, MD

Santosh Kesari
MD, PhD, FANA, FAAN

Clinical Trial Team

Najee Boucher, CRA
najee.boucher@providence.org
310-582-7460

Annie Heng, RN, BSN
HengA@jwci.org
310-582-7457

Marlon Garzo Saria,
MSN, RN, AOCNS, FAAN
SariaM@jwci.org
310-582-7340

Sponsor

Nativis, Inc.

Please feel free to contact the clinical trial team to learn more about this study.

CLINICAL TRIAL ANNOUNCEMENT

A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy.

Nativis Voyager™ System:

A non-invasive, non-thermal, battery-operated, mobile investigational medical device that is placed on the patient's head above the target treatment site (solid tumor). The device provides anti-cancer treatment through the emission of continuous, low level radio frequency energy (RFE). A treatment cycle is defined as 28 days of investigational treatment (Voyager therapy) administered to the head (non-invasively) continuously for 24 hours per day 7 days per week. Therapy may be periodically halted for short periods (under one hour in duration) to allow for routine maintenance (e.g., battery change) and daily home care (e.g., showering).

Patients with recurrent GBM and have either failed prior standard-of-care therapy, including radiation therapy and/or chemotherapy, or are intolerant of therapy will be considered for inclusion in the study. Patients who have additionally received other investigational therapies that are no longer effective for the given patient or are intolerant to the investigational therapy may be considered for inclusion in this study.

Inclusion Criteria:

- Histologically confirmed diagnosis of GBM.
- Failed or intolerant to radiotherapy.
- Failed or intolerant to temozolomide therapy.
- Progressive disease with at least one measureable lesion on MRI or CT.
- At least 18 years of age.
- KPS \geq 60.
- Adequate organ and marrow function.
- Signed informed consent.

Please feel free to contact the clinical trial team to learn more about this study.